Davenportgoldberg2261

Seventy eight (28%) patients had trapped lung; 27 of those had a repeat procedure. The median length of stay was 3.96days. There was one hospital death (0.3% mortality). Complications of LAT included pleural (3, 1%) and wound infections (4, 1.4%), persistent air leaks (9, 3.2%), subcutaneous emphysema (10, 3.6%), and tumor extension to the access port (1, 0.3%).

In this cohort, LAT was safe, effective, and enabled high diagnostic sensitivity. Further areas of study include optimal sedation and anesthetic pathways and combining LAT with indwelling pleural catheters (IPC).

In this cohort, LAT was safe, effective, and enabled high diagnostic sensitivity. Further areas of study include optimal sedation and anesthetic pathways and combining LAT with indwelling pleural catheters (IPC).

Malignant pleural effusion (MPE) is a devastating evolution of several malignancies. Pressurized intrathoracic aerosol chemotherapy (PITAC) might be a novel therapy option in MPE.

PITAC is considered for patients with MPE with a performance status <2 and without other metastatic sites. General anesthesia is administered and a double-lumen bronchial tube is inserted. The patient is placed in a lateral decubitus position, and the operation is performed after ipsilateral lung exclusion. Two 12-mm balloon trocars are inserted-one in the seventh intercostal space in the mid-axillary line and one in the fifth intercostal space in the anterior axillary line. Extent of pleural disease and volume of MPE are documented. MPE is removed and parietal pleural biopsy are performed. An intrathoracic pressure of 12mmHg CO

is established, and a combination of Cisplatin (10.5mg/m

in a total volume of 150cc NaCl 0.9%) and Doxorubicin (2.1mg/m

in a total volume of 50cc NaCl 0.9%) are aerosolized via nebulizer in the pleural cavity. Vital signs and nebulization are remote-controlled. After 30min, the remaining toxic aerosol is exhausted using a closed surgical smoke evacuation system. A 24Fr chest tube is inserted in postero-apical position with continuous negative pressure of 20cm H

O. When needed, PITAC may be repeated every six weeks in alternate with systemic chemotherapy.

In our hands, the technique above has shown to be feasible and safe.

Further studies are needed to assess the potential symptomatic and oncological benefits of PITAC in MPE.

Further studies are needed to assess the potential symptomatic and oncological benefits of PITAC in MPE.

To study the expression of growth factors in the regulation of tissue repair after peritoneal damage tissue response to peritoneal damage.

Experimental study in 35 male Wistar rats determining the evolution over time of the tissue response to aseptic peritoneal damage. A standardized bowel and peritoneal lesions were created in the right lower quadrant by laparotomy. Then, tissular expression of growth factors was evaluated by multiplex polymerase chain reaction at seven timepoints between 6h and 30days, postoperatively.

Tissular responses of granulocyte-stimulating factors (Csf2, Csf3), connective tissue growth factor (Ctgf), epidermal growth factors and receptor (Egf, Egfr), fibroblast growth factors (Fgf2, 7 and 10), heparin binding EGF-like growth factor (Hbegf), hepatocyte growth factor (Hgf), insulin-like growth factor-1 (Igf1), mitogenic transforming growth factors (Tgfa, Tgfb1, Tgfbr3), and vascular endothelial growth factor A (Vegfa) were biphasic with a first expression peak at day 3, followed by a more pronounced peak at day 14.

We observed a long-lasting, widespread response of tissular growth factors for at least two weeks after peritoneal damage. To be clinically effective, the prophylaxis of postoperative adhesions might be needed for an extended period of time.

We observed a long-lasting, widespread response of tissular growth factors for at least two weeks after peritoneal damage. To be clinically effective, the prophylaxis of postoperative adhesions might be needed for an extended period of time.Pressurised IntraPeritoneal Aerosol Chemotherapy (PIPAC) is a novel surgical technique to administer aerosolized chemotherapy into the abdominal cavity as treatment for peritoneal metastasis from various cancers. As the surgery is unique and there are concerns about occupational hazards, specific anaesthetic setup and techniques are required. Notably, our institution's experience with PIPAC has enlightened us that anaesthesia requirements during PIPAC are generally uncomplicated and that the majority of the patients undergoing PIPAC do not require invasive monitoring, advanced intra or postoperative analgesia like epidurals or PCA. BMH21 The need for postoperative intensive unit care is also not required in routine PIPAC cases. We describe the anaesthetic considerations involved and the detailed preparation of staff, space, anaesthetic equipment and drugs to facilitate the appropriate modifications for anaesthesia monitoring and maintenance for an elective set up as well as our standard operating procedure for an emergency situation should it arise.[This corrects the article DOI 10.1016/j.ijnss.2020.06.010.][This corrects the article DOI 10.1016/j.ijnss.2018.01.001.][This corrects the article DOI 10.1016/j.ijnss.2017.12.008.][This corrects the article DOI 10.1016/j.ijnss.2020.04.002.][This corrects the article DOI 10.1016/j.ijnss.2018.03.006.][This corrects the article DOI 10.1016/j.ijnss.2018.03.005.][This corrects the article DOI 10.1016/j.ijnss.2018.04.008.][This corrects the article DOI 10.1016/j.ijnss.2018.06.005.][This corrects the article DOI 10.1016/j.ijnss.2017.12.007.][This corrects the article DOI 10.1016/j.ijnss.2018.07.005.][This corrects the article DOI 10.1016/j.ijnss.2019.06.004.][This corrects the article DOI 10.1016/j.ijnss.2020.06.009.][This corrects the article DOI 10.1016/j.ijnss.2018.04.002.][This corrects the article DOI 10.1016/j.ijnss.2018.04.012.].[This corrects the article DOI 10.1016/j.ijnss.2018.01.004.][This corrects the article DOI 10.1016/j.ijnss.2018.03.004.][This corrects the article DOI 10.1016/j.ijnss.2018.03.008.][This corrects the article DOI 10.1016/j.ijnss.2020.03.006.][This corrects the article DOI 10.1016/j.ijnss.2018.06.002.][This corrects the article DOI 10.1016/j.ijnss.2018.03.003.][This corrects the article DOI 10.1016/j.ijnss.2018.07.004.][This corrects the article DOI 10.1016/j.ijnss.2018.04.007.][This corrects the article DOI 10.1016/j.ijnss.2020.05.007.][This corrects the article DOI 10.1016/j.ijnss.2018.09.007.][This corrects the article DOI 10.1016/j.ijnss.2018.04.005.][This corrects the article DOI 10.1016/j.ijnss.2020.07.007.][This corrects the article DOI 10.1016/j.ijnss.2018.03.001.][This corrects the article DOI 10.1016/j.ijnss.2018.12.007.][This corrects the article DOI 10.1016/j.ijnss.2018.06.006.].